Cytomegalovirus reactivation in patients diagnosed with severe COVID-19: A point prevalence study in a general hospital.

IF 1.9 4区医学 Q4 MICROBIOLOGY

Revista Espanola De Quimioterapia Pub Date : 2023-02-01 DOI:10.37201/req/068.2022

M J Pérez-Granda, P Catalán, P Muñoz, T Aldámiz, J C Barrios, C Ramírez, R García-Martínez, M V Villalba, L Puente, E Bouza

{"title":"Cytomegalovirus reactivation in patients diagnosed with severe COVID-19: A point prevalence study in a general hospital.","authors":"M J Pérez-Granda, P Catalán, P Muñoz, T Aldámiz, J C Barrios, C Ramírez, R García-Martínez, M V Villalba, L Puente, E Bouza","doi":"10.37201/req/068.2022","DOIUrl":null,"url":null,"abstract":"Objective: To determine the prevalence of CMV reactivation in a population admitted for severe COVID-19 to a general hospital.Methods: Point prevalence study in all hospitalized patients with severe COVID-19 (admitted either to general wards or ICU). Determination of the presence of CMV DNA in circulating blood. COVID-19 was confirmed in patients with compatible clinical manifestations, usually with pneumonia and a positive nasopharyngeal PCR test.Results: We included 140 hospitalized patients with COVID-19 who consented to participate. A total of 16 patients (11.42%), had circulating CMV-DNA in peripheral blood at the time of the study. Patients with positive CMV viral load were mainly ICU patients (11/37 -29,7%) and only 5/103 cases (4,85%) were hospitalized into general wards. The accumulated doses of corticosteroids (prednisone equivalents) in the study day were (median and IQR) 987.50 mg (396.87-2,454.68) and 187.50 mg (75.00-818.12) respectively in CMV positive and negative patients (p < 0.001). A significant proportion of CMV positive patients were discovered because of the study and were clinically unsuspected by their physicians. The coinfected COVID-CMV positive population had a higher risk of accumulated secondary nosocomially-acquired infections and a worse prognosis.Conclusions: CMV reactivation should be systematically searched in patients in COVID-19 cases admitted to the ICU.","PeriodicalId":21232,"journal":{"name":"Revista Espanola De Quimioterapia","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d4/46/revespquimioter-36-045.PMC9910675.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Espanola De Quimioterapia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.37201/req/068.2022","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MICROBIOLOGY","Score":null,"Total":0}

引用次数: 2

Abstract

Objective: To determine the prevalence of CMV reactivation in a population admitted for severe COVID-19 to a general hospital.

Methods: Point prevalence study in all hospitalized patients with severe COVID-19 (admitted either to general wards or ICU). Determination of the presence of CMV DNA in circulating blood. COVID-19 was confirmed in patients with compatible clinical manifestations, usually with pneumonia and a positive nasopharyngeal PCR test.

Results: We included 140 hospitalized patients with COVID-19 who consented to participate. A total of 16 patients (11.42%), had circulating CMV-DNA in peripheral blood at the time of the study. Patients with positive CMV viral load were mainly ICU patients (11/37 -29,7%) and only 5/103 cases (4,85%) were hospitalized into general wards. The accumulated doses of corticosteroids (prednisone equivalents) in the study day were (median and IQR) 987.50 mg (396.87-2,454.68) and 187.50 mg (75.00-818.12) respectively in CMV positive and negative patients (p < 0.001). A significant proportion of CMV positive patients were discovered because of the study and were clinically unsuspected by their physicians. The coinfected COVID-CMV positive population had a higher risk of accumulated secondary nosocomially-acquired infections and a worse prognosis.

Conclusions: CMV reactivation should be systematically searched in patients in COVID-19 cases admitted to the ICU.

Abstract Image

查看原文本刊更多论文

重症COVID-19患者巨细胞病毒再激活:某综合医院点流行病学研究

目的:了解某综合医院重症COVID-19患者中巨细胞病毒再激活的流行情况。方法:对所有重症COVID-19住院患者(普通病房或ICU)进行点流行病学研究。循环血液中巨细胞病毒DNA存在的测定。临床表现符合的患者确诊为COVID-19，通常伴有肺炎和鼻咽PCR检测阳性。结果:我们纳入了140名同意参与的住院COVID-19患者。在研究期间，共有16名患者(11.42%)外周血中有循环CMV-DNA。CMV病毒载量阳性患者以ICU患者为主(11/37 ~ 29.7%)，仅5/103例(4.85%)入住普通病房。在研究日中，CMV阳性和阴性患者皮质类固醇(强的松当量)的累积剂量(中位数和IQR)分别为987.50 mg(396.87-2,454.68)和187.50 mg (75.00-818.12) (p < 0.001)。很大比例的巨细胞病毒阳性患者是由于这项研究而被发现的，他们的医生在临床上没有怀疑。冠状病毒-巨细胞病毒合并感染人群累积继发性医院获得性感染风险较高，预后较差。结论:在ICU收治的COVID-19患者中应系统地搜索CMV再激活情况。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Revista Espanola De Quimioterapia 医学-药学

CiteScore

2.90

自引率

10.50%

发文量

146

审稿时长

>12 weeks

期刊介绍： The official journal of the Sociedad Española de Quimioterapia (Spanish Society of Chemotherapy), publishes articles that further knowledge and advance the science and application of antimicrobial chemotherapy with antibiotics and antifungal, antiviral and antiprotozoal agents primarily in human medicine. Authors sign an exclusive license agreement, where authors have copyright but license exclusive rights in their article to the Publisher. All manuscripts are free open access. Revista Española de Quimioterapia includes the following sections: reviews, original articles, brierf reports, letters, and consensus documents.